EPHA5 mutation was associated with adverse outcome of atezolizumab treatment in late-stage non-small cell lung cancers

BACKGROUND: The aim of the study was to investigate predictive value of gene mutation for atezolizumab treatment response from OAK and POPLAR cohorts. METHODS: Several public databases were used for analyzing gene mutation type of EPHA5 and association with alterations of other genes. Survival analy...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zhenxiang, Zhou, Qing, Wang, Qi, Wang, Haiyong, Yue, Weiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487080/
https://www.ncbi.nlm.nih.gov/pubmed/36123678
http://dx.doi.org/10.1186/s12890-022-02161-1
_version_ 1784792417128415232
author Li, Zhenxiang
Zhou, Qing
Wang, Qi
Wang, Haiyong
Yue, Weiming
author_facet Li, Zhenxiang
Zhou, Qing
Wang, Qi
Wang, Haiyong
Yue, Weiming
author_sort Li, Zhenxiang
collection PubMed
description BACKGROUND: The aim of the study was to investigate predictive value of gene mutation for atezolizumab treatment response from OAK and POPLAR cohorts. METHODS: Several public databases were used for analyzing gene mutation type of EPHA5 and association with alterations of other genes. Survival analysis was performed for patients receiving atezolizumab from OAK and POPLAR cohorts. RESULTS: EPHA5 mutation have high frequency to harbor TP53 and KEAP1 mutations. The bTMB value has significant difference between EPHA5 mutant and wild-type cases. Patients with EPHA5 mutation got worse survival compared to those without gene mutations receiving atezolizumab (P = 0.0186). CONCLUSIONS: EPHA5 mutant NSCLC may represent a subpopulation which showed worse response after treatment of atezolizumab compared to wild-type ones. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-022-02161-1.
format Online
Article
Text
id pubmed-9487080
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-94870802022-09-21 EPHA5 mutation was associated with adverse outcome of atezolizumab treatment in late-stage non-small cell lung cancers Li, Zhenxiang Zhou, Qing Wang, Qi Wang, Haiyong Yue, Weiming BMC Pulm Med Research BACKGROUND: The aim of the study was to investigate predictive value of gene mutation for atezolizumab treatment response from OAK and POPLAR cohorts. METHODS: Several public databases were used for analyzing gene mutation type of EPHA5 and association with alterations of other genes. Survival analysis was performed for patients receiving atezolizumab from OAK and POPLAR cohorts. RESULTS: EPHA5 mutation have high frequency to harbor TP53 and KEAP1 mutations. The bTMB value has significant difference between EPHA5 mutant and wild-type cases. Patients with EPHA5 mutation got worse survival compared to those without gene mutations receiving atezolizumab (P = 0.0186). CONCLUSIONS: EPHA5 mutant NSCLC may represent a subpopulation which showed worse response after treatment of atezolizumab compared to wild-type ones. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-022-02161-1. BioMed Central 2022-09-19 /pmc/articles/PMC9487080/ /pubmed/36123678 http://dx.doi.org/10.1186/s12890-022-02161-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Li, Zhenxiang
Zhou, Qing
Wang, Qi
Wang, Haiyong
Yue, Weiming
EPHA5 mutation was associated with adverse outcome of atezolizumab treatment in late-stage non-small cell lung cancers
title EPHA5 mutation was associated with adverse outcome of atezolizumab treatment in late-stage non-small cell lung cancers
title_full EPHA5 mutation was associated with adverse outcome of atezolizumab treatment in late-stage non-small cell lung cancers
title_fullStr EPHA5 mutation was associated with adverse outcome of atezolizumab treatment in late-stage non-small cell lung cancers
title_full_unstemmed EPHA5 mutation was associated with adverse outcome of atezolizumab treatment in late-stage non-small cell lung cancers
title_short EPHA5 mutation was associated with adverse outcome of atezolizumab treatment in late-stage non-small cell lung cancers
title_sort epha5 mutation was associated with adverse outcome of atezolizumab treatment in late-stage non-small cell lung cancers
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487080/
https://www.ncbi.nlm.nih.gov/pubmed/36123678
http://dx.doi.org/10.1186/s12890-022-02161-1
work_keys_str_mv AT lizhenxiang epha5mutationwasassociatedwithadverseoutcomeofatezolizumabtreatmentinlatestagenonsmallcelllungcancers
AT zhouqing epha5mutationwasassociatedwithadverseoutcomeofatezolizumabtreatmentinlatestagenonsmallcelllungcancers
AT wangqi epha5mutationwasassociatedwithadverseoutcomeofatezolizumabtreatmentinlatestagenonsmallcelllungcancers
AT wanghaiyong epha5mutationwasassociatedwithadverseoutcomeofatezolizumabtreatmentinlatestagenonsmallcelllungcancers
AT yueweiming epha5mutationwasassociatedwithadverseoutcomeofatezolizumabtreatmentinlatestagenonsmallcelllungcancers

Ejemplares similares